Pulmonary hypertension in adults completing tuberculosis treatment
Article Sidebar
Main Article Content
Abstract
Background. Pulmonary hypertension (PH) after tuberculosis (TB) is typically not included among the chronic lung diseases causing PH (group 3 PH), with few data available to support the inclusion.
Objectives. To determine the prevalence of PH in an adult population completing TB treatment.
Methods. This single-centre, cross-sectional study only included patients with their first documented episode of TB, and who were in the second half of treatment or had recently completed treatment. PH was assessed using transthoracic echocardiography. Questionnaires were also completed and spirometry and a 6-minute walk test were performed.
Results. One hundred patients were enrolled, with a mean age of 37.1 years, of whom 58% were male and 46% HIV positive. The median time since initiation of TB treatment was 22 weeks. The mean (standard deviation) measured right ventricular systolic pressure (RVSP) was 23.6 (6.24) mmHg. One participant had PH (defined as RVSP ≥40 mmHg; 95% confidence interval (CI) 0.0 - 3.0) and a further 3 had possible PH (RVSP ≥35 and <40 mmHg), with a combined PH prevalence of 4% (95% CI 0.2 - 7.8). Airflow obstruction on spirometry was found in 13.3% of 98 patients, while 25.5% had a reduced forced vital capacity. There was no association between RVSP or PH/possible PH and sex, age, HIV status, systemic hypertension, spirometry measurements or 6-minute walking distance. Smoking status was associated with RVSP, but not with the presence of PH/possible PH.
Conclusion. There was a significant prevalence of PH in this preliminary study of predominantly young patients completing treatment for a first episode of TB. Larger and more detailed studies are warranted.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016;4(4):306-322. https://doi.org/10.1016/S2213-2600(15)00543-3 2. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;53(1):1801914. https://doi.
org/10.1183/13993003.01914-2018
Enea I, Ghio S, Bongarzoni A, et al. [Echocardiographic alterations suggestive of pulmonary hypertension in the Italian ultrasonography laboratories. Epidemiological data from the INCIPIT study (INCidence of Pulmonary Hypertension in Italian ulTrasonography laboratories)]. G Ital Cardiol (Rome) 2010;11(5):402-407.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237
Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: A modelling study. Lancet Infect Dis 2021;21(7):984-992. https://doi.org/10.1016/S1473-3099(20)30919-1
Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: Perspectives from the First International Symposium. Int J Tuberc Lung Dis 2020;24(8):820-828. https://doi.org/10.5588/ijtld.20.0067
Samuelsson S. Chronic cor pulmonale in pulmonary tuberculosis. Acta Med Scand 1952;142(5):315-324. https://doi.org/10.1111/j.0954-6820.1952.tb13871.x
Walzer I, Frost T. Cor pulmonale: A consideration of clinical and autopsy findings. Dis Chest 1954;26(2):192-198.
Chen Y, Liu C, Lu W, et al. Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: A retrospective study. J Thorac Dis 2016;8(3):350-358. https://doi.org/10.21037/jtd.2016.02.58
Allwood BW, Maarman GJ, Kyriakakis CG, Doubell AF. Post-pulmonary tuberculosis complications in South Africa and a potential link with pulmonary hypertension: Premise for clinical and scientific investigations. S Afr Med J 2018;108(7):529. https:// doi.org/10.7196/SAMJ.2018.v108i7.13359
Marjani M, Baghaei P, Malekmohammad M, et al. Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. Braz J Infect Dis 2014;18(5):487-490. https:// doi.org/10.1016/j.bjid.2014.02.006
Akkara AS, Shah AD, Adalja M, Akkara AG, Rathi A, Shah DN. Pulmonary tuberculosis: The day after. Int J Tuberc Lung Dis 2013;17(6):810-813. https://doi. org/10.5588/ijtld.12.0317
Vyslouzil Z, Polak J, Widimsky J, Sukova M. Pathogenesis of pulmonary hypertension in tuberculosis. Czech Med 1980;3(2):123-131.
Graham BL, Steenbruggen I, Miller MR, et al. Standardisation of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200(8):e70-e88. https://doi. org/10.1164/rccm.201908-1590ST
Zaidi A, Knight DS, Augustine DX, et al.; British Society for Echocardiography. Echocardiographic assessment of the right heart in adults: A practical guideline from the British Society of Echocardiography. Echo Res Pract 2020;7(1):G19-G41. https:// doi.org/10.1530/ERP-19-0051
Huluka DK, Mekonnen D, Abebe S, et al. Prevalence and risk factors of pulmonary hypertension among adult patients with HIV infection in Ethiopia. Pulm Circ 2020;10(4):2045894020971518. https://doi.org/10.1177/2045894020971518
Allwood BW, Maasdorp E, Kim GJ, et al. Transition from restrictive to obstructive lung function impairment during treatment and follow-up of active tuberculosis. Int J Chron Obstruct Pulmon Dis 2020;15:1039-1047. https://doi.org/10.2147/COPD.S219731
MeghjiJ,LesoskyM,JoekesE,etal.Patientoutcomesassociatedwithpost-tuberculosis lung damage in Malawi: A prospective cohort study. Thorax 2020;75(3):269-278. https://doi.org/10.1136/thoraxjnl-2019-213808
Kalla IS, Miri A, Seedat F. Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. Afr J Thorac Crit Care Med 2020;26(4):133-137. https://doi.org/10.7196/AJTCCM.2020.v26i4.110
Keusch S, Hildenbrand FF, Bollmann T, et al. Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. Respiration 2014;88(1):38-45. https://doi.org/10.1159/000359972
Huang SK. Knocking out smoking and pulmonary hypertension with a K. Am J Respir Crit Care Med 2021;203(10):1216-1218. https://doi.org/10.1164/rccm.202011-4121ED 22. Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post- tuberculosis lung disease: Clinical review of an under-recognised global challenge.
Respiration 2021;100(8):751-763. https://doi.org/10.1159/000512531
Ahmed AEH, Ibrahim AS, Elshafie SM. Pulmonary hypertension in patients with treated pulmonary tuberculosis: Analysis of 14 consecutive cases. Clin Med Insights
Circ Respir Pulm Med 2011;5:1-5. https://doi.org/10.4137/CCRPM.S6437
RichJD,ShahSJ,SwamyRS,KampA,RichS.InaccuracyofDopplerechocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: Implications for clinical practice. Chest 2011;139(5):988-993. https://doi.org/10.1378/
chest.10-1269